Skip to main content
Healthcare professionals

Why prescribe this test?

An overview for doctors: what the test measures, how to interpret the result and where it fits in your patients' preventive care pathway.

We work with functional medicine doctors committed to preventive healthcare.

What the test measures

The hPG80 protein, measured with a simple blood test.

The test measures hPG80, or circulating progastrin, using a quantitative ELISA assay performed in a laboratory on a simple blood sample. It is a CE-marked test.

16 types of solid cancer

Elevated hPG80 levels have been observed at every stage.

The data

26 studies, 4,045 cancer patients and 1,199 healthy people.

A doctor talking with a female patient in a simple consulting room lit by daylight

Median hPG80 level by cancer stage

pmol/L

Detection threshold (intermediate): 3.3 pmol/L (intermediate threshold; high levels above 10,90 pmol/L)
Healthy individuals
n = 1 199
Stage I
n = 390
Stage II
n = 374
Stage III
n = 284
Stage IV
n = 1 581
hPG80 levels are already higher at stage I and remain higher at every stage. Above 3.3 pmol/L, the level is considered intermediate; above 10.9 pmol/L, it is considered high.¹
Interpreting the result

A result in 3 ranges.

Low level

< 3.3 pmol/L

Result in the low range.

Intermediate level

3.3 to 10.9 pmol/L

Interpret in the clinical context, alongside other tests and a repeat measurement.

High level

> 10.9 pmol/L

Further tests, guided by clinical findings, often including imaging.

Factors that can raise levels without cancer

Active smoking and COPD can raise hPG80 levels. After quitting smoking, the level may return to the low range within the following month.¹

Learn more in the FAQ →
hPG80 levels in non-smokers, smokers and former smokers
hPG80 levels by smoking status.²

The role of the test

It is an aid to cancer detection, complementing organised screening, never replacing it. It does not locate the tumour.

Who is it for?

For people without symptoms who want to take a preventive approach. If symptoms are present, the usual medical assessment takes priority.

Panel of doctors

Join our panel to support our clients

Join our panel

Sources

  1. 1.biodena.care
  2. 2.Vire et al., Biomarker Research, 2025
  3. 3.You et al., EBioMedicine, 2020